Pharmacopsychiatry 2012; 45(06): 223-228
DOI: 10.1055/s-0031-1301365
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Insulin Secretion and Sensitivity after Single-Dose Amisulpride, Olanzapine or Placebo in Young Male Subjects: Double Blind, Cross-Over Glucose Clamp Study

D. Kopf*
1   Central Institute of Mental Health, University of Heidelberg, Faculty of Medicine, Mannheim, Germany
2   Marienkrankenhaus, Department of Geriatric Medicine, Hamburg, Germany
,
M. Gilles*
1   Central Institute of Mental Health, University of Heidelberg, Faculty of Medicine, Mannheim, Germany
,
G. Paslakis
1   Central Institute of Mental Health, University of Heidelberg, Faculty of Medicine, Mannheim, Germany
,
F. Medlin
1   Central Institute of Mental Health, University of Heidelberg, Faculty of Medicine, Mannheim, Germany
,
F. Lederbogen
1   Central Institute of Mental Health, University of Heidelberg, Faculty of Medicine, Mannheim, Germany
,
H. Lehnert
3   1st Medical Department, University of Lübeck Medical School, Luebeck, Germany
,
M. Deuschle
1   Central Institute of Mental Health, University of Heidelberg, Faculty of Medicine, Mannheim, Germany
› Author Affiliations
Further Information

Publication History

received 01 September 2011
revised 09 January 2012

accepted 10 January 2012

Publication Date:
16 March 2012 (online)

Abstract

Introduction:

Increased risks of weight gain and diabetes mellitus have been reported for schizophrenic patients under long-term treatment with several atypical antipsychotic drugs including olanzapine. Among other antipsychotic drugs, treatment with the selective dopamine D2 and D3 receptor antagonist amisulpride has been implicated with a lower risk for metabolic complications.

Patients and Methods:

In this study we compared the acute, non-adiposity related effects of a single dose of olanzapine, amisulpride and placebo on insulin sensitivity and secretion in 10 healthy subjects in a randomised, double blind cross-over design. Subjects underwent euglycemic-hyperinsulinemic and hyperglycemic clamp tests using an automated clamp device. C-peptide and pro-insulin levels were determined using highly specific immuno-assays.

Results:

Insulin sensitivity was not significantly different between both verum medications and placebo. However, C-peptide secretion during hyperglycemic clamp was significantly higher after administration of amisulpride than after olanzapine or placebo. This was true both for the early phase and for the second phase of insulin secretion (C-peptide at 0, 5,10 and 30 min: amisulpride 1.49±0.49; 4.22±1.45; 3.19±1.22; 5.33±1.85; olanzapine 1.35±0.47; 3.84±1.37; 2.72±0.91; 4.28±1.96; placebo 1.72±0.82; 3.59±1.19; 2.71±1.02; 4.54±1.42 ng/mL, mean±SD; ANOVA p=0.043). Pro-insulin levels did not differ significantly between groups.

Discussion:

A low dose of the D2/D3 antagonist amisulpride, but not olanzapine appears to acutely increase pancreatic insulin secretion in healthy controls. Stimulation of β-cells could be a protective factor against the development of diabetes mellitus.

*

* These authors contributed equally to this work


 
  • References

  • 1 Meyer JM, Nasrallah HA, McEvoy JP et al. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res 2005; 80: 9-18
  • 2 McEvoy JP, Meyer JM, Goff DC et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19-32
  • 3 De Hert M, van Eyck D, De Nayer A. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 2006; 21 (Suppl. 02) S11-S15
  • 4 Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596-601
  • 5 Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 2005; 66: 504-514
  • 6 Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 (Suppl. 01) 1-93
  • 7 Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223
  • 8 Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000; 61: 742-749
  • 9 Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001; 21: 369-374
  • 10 Lindenmayer JP, Smith RC, Singh A et al. Hyperglycemia in patients with schizophrenia who are treated with olanzapine. J Clin Psychopharmacol 2001; 21: 351-353
  • 11 Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl) 2003; 170: 157-166
  • 12 Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 2001; 15: 537-551
  • 13 Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 2005; 19: 16-27
  • 14 Tschoner A, Engl J, Laimer M et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract 2007; 61: 1356-1370
  • 15 Rettenbacher MA, Hummer M, Hofer A et al. Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study. J Psychopharmacol 2007; 21: 400-404
  • 16 Koller E, Schneider B, Bennett K et al. Clozapine-associated diabetes. Am J Med 2001; 111: 716-723
  • 17 Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002; 22: 841-852
  • 18 Vidarsdottir S, Roelfsema F, Frolich M et al. Olanzapine shifts the temporal relationship between the daily acrophase of serum prolactin and cortisol concentrations rhythm in healthy men. Psychoneuroendocrinology 2009; 34: 705-712
  • 19 Henderson DC, Cagliero E, Copeland PM et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005; 62: 19-28
  • 20 Chintoh AF, Mann SW, Lam L et al. Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. J Clin Psychopharmacol 2008; 28: 494-499
  • 21 Lin CC, Bai YM, Wang YC et al. Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics. J Clin Psychopharmacol 2009; 29: 529-536
  • 22 Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004; 65 (Suppl. 18) 36-46
  • 23 Elahi D. In praise of the hyperglycemic clamp. A method for assessment of beta-cell sensitivity and insulin resistance. Diabetes Care 1996; 19: 278-286
  • 24 Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens 1998; 16: 895-906
  • 25 Pittasch D, Kanneberg E, Kopf D et al. A novel computerized glucose clamp technique (Abstract). 63rd Scientific Meeting of the American Diabetes Association, New Orleans, LA, June 13–17, 2003. Diabetes 2003; 52 (Suppl A): 436
  • 26 DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-E223
  • 27 Burns SF, Bacha F, Lee SJ et al. Declining β-cell function relative to insulin sensitivity with escalating OGTT 2-h glucose concentrations in the nondiabetic through the diabetic range in overweight youth. Diabetes Care 2011; 34: 2033-2040
  • 28 Bymaster FP, Calligaro DO, Falcone JF et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14: 87-96
  • 29 Yavuz D, Deyneli O, Akpinar I et al. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol 2003; 149: 187-193
  • 30 Gilles M, Wilke A, Kopf D et al. Antagonism of the serotonin (5-HT)-2 receptor and insulin sensitivity: implications for atypical antipsychotics. Psychosom Med 2005; 67: 748-751
  • 31 Pollare T, Lithell H, Selinus I et al. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988; 31: 415-420
  • 32 Giorda C, Appendino M, Mason MG et al. Alpha 1-blocker doxazosin improves peripheral insulin sensitivity in diabetic hypertensive patients. Metabolism 1995; 44: 673-676
  • 33 Sowell M, Mukhopadhyay N, Cavazzoni P et al. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab 2003; 88: 5875-5880
  • 34 Ader M, Kim SP, Catalano KJ et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease. A placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005; 54: 862-871
  • 35 Houseknecht KL, Robertson AS, Zavadoski W et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007; 32: 289-297
  • 36 Henderson DC, Copeland PM, Borba CP et al. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry 2006; 67: 789-797
  • 37 Engl J, Laimer M, Niederwanger A et al. Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol Psychiatry 2005; 10: 1089-1096
  • 38 Ericson LE, Hakanson R, Lundquist I. Accumulation of dopamine in mouse pancreatic B-cells following injection of L-DOPA. Localization to secretory granules and inhibition of insulin secretion. Diabetologia 1997; 13: 117-124
  • 39 Raedler TJ, Knable MB, Jones DW et al. In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Neuropsychopharmacology 2000; 23: 56-68
  • 40 Lundquist I. Cholinergic muscarinic effects on insulin release in mice. Pharmacology 1982; 25: 338-347
  • 41 Duttaroy A, Zimliki CL, Gautam D et al. Muscarinic stimulation of pancreatic insulin and glucagon release is abolished in m3 muscarinic acetylcholine receptor-deficient mice. Diabetes 2004; 53: 1714-1720
  • 42 Fernandez-Egea E, Miller B, Garcia-Rizo C et al. Metabolic effects of olanzapine in patients with newly diagnosed psychosis. J Clin Psychopharmacol 2011; 31: 154-159
  • 43 Melkersson K. Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro. Eur Neuropsychopharmacol 2004; 14: 115-119
  • 44 Joost HG, Göke B, Hasselblatt A. Effects of pimozide and apomorphine on insulin secretion from the perfused rat pancreas. Arch Int Pharmacodyn Ther 1983; 263: 155-163
  • 45 Burns SF, Bacha F, Lee SJ et al. Declining beta-cell function relative to insulin sensitivity with escalating OGTT 2-h glucose concentrations in the nondiabetic through the diabetic range in overweight youth. Diabetes Care 2011; 34: 2033-2040
  • 46 Hambrock A, de Oliveira Franz CB, Hiller S et al. Glibenclamide-induced apoptosis is specifically enhanced by expression of the sulfonylurea receptor isoform SUR1 but not by expression of SUR2B or the mutant SUR1(M1289T). J Pharmacol Exp Ther 2006; 316: 1031-1037
  • 47 Chenda C, Zhou MA, Zhou DH et al. Gender differences in the prevalence of diabetes mellitus in chronic hospitalized patients with schizophrenia on long-term antipsychotics. Psychiatry Res 2011; 186: 451-453
  • 48 Ryan AS, Muller DC, Elahi D. Sequential hyperglycemic-euglycemic clamp to assess beta-cell and peripheral tissue: studies in female athletes. J Appl Physiol 2001; 91: 872-881
  • 49 Xiao C, Giacca A, Lewis GF. The effect of high-dose sodium salicylate on chronically elevated plasma non-esterified fatty acid-induced insulin resistance and beta-cell dysfunction. Am J Physiol Endocrinol Metab 2009; Sep 15
  • 50 Dinan TG. Stress and the genesis of diabetes mellitus in schizophrenia. Br J Psychiatry Suppl 2004; 47: S72-S75